Dr. Sanda is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
PO Box
Bldg B
Atlanta, GA 30322Phone+1 404-778-6874
Summary
- Dr. Martin Sanda is Professor and Chair of Urology at Emory Healthcare in Atlanta, GA and is affiliated with multiple hospitals in the area, including Emory University Hospital, Emory Saint Joseph's Hospital of Atlanta, and others. He received his medical degree from Columbia University College of Physicians & Surgeons, completed his Urology residency at Johns Hopkins, and has been in practice 25 years. He specializes in urological oncology with focus on prostate cancer, and has managed the care and treatment of over 2500 men with newly diagnosed prostate cancer.
Education & Training
- Johns Hopkins UniversityResidency, Urology, 1991 - 1995
- National Cancer InstituteFellowship, Tumor Immunology, 1989 - 1991
- Virginia Commonwealth University Health SystemResidency, Surgery, 1987 - 1989
- Columbia University Vagelos College of Physicians and SurgeonsClass of 1987
Certifications & Licensure
- GA State Medical License 2013 - 2026
- MA State Medical License 2003 - 2014
- MI State Medical License 1995 - 2005
- MD State Medical License 1989 - 1995
- American Board of Urology Urology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2009-2013
- Boston Magazine Castle Connolly, 2008-2012
Clinical Trials
- Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer Start of enrollment: 2002 Sep 01
- Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Start of enrollment: 2007 May 08
- Observation or Radical Treatment in Patients With Prostate Cancer Start of enrollment: 2007 Dec 06
- Join now to see all
Publications & Presentations
PubMed
- Differentiation fate of a stem-like CD4 T cell controls immunity to cancer.Maria A Cardenas, Nataliya Prokhnevska, Ewelina Sobierajska, Petra Gregorova, Christopher B Medina
Nature. 2024-12-01 - Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort.Michael A Liss, Nicole Zeltser, Yingye Zheng, Camden Lopez, Menghan Liu
Cancer Epidemiology, Biomarkers & Prevention. 2024-11-01 - Author Correction: Differentiation fate of a stem-like CD4 T cell controls immunity to cancer.Maria A Cardenas, Nataliya Prokhnevska, Ewelina Sobierajska, Petra Gregorova, Christopher B Medina
Nature. 2024-11-01
Journal Articles
- Impact of Prebiopsy Magnetic Resonance Imaging of the Prostate on Cancer Detection and Treatment PatternsMartin G Sanda, Christopher P Filson, Urologic Oncology
Press Mentions
- Immune Cell Find Boosts Cancer Immunotherapy HopesOctober 26th, 2024
- Immune Cell Discovery Offers New Potential for Cancer ImmunotherapyOctober 25th, 2024
- Research Roundup: Recent Grants and Publications for Emory Faculty and StaffNovember 9th, 2021
- Join now to see all
Grant Support
- Harvard/Michigan/Cornell Prostate Cancer Biomarker Clinical Validation CenterNational Cancer Institute2010–2011
- Effectiveness Of Robotic Compared To Standard Prostatectomy For Prostate CancerNational Institute Of Biomedical Imaging And Bioengineering2009–2010
- Effectiveness Of Early Stage Prostate Cancer TreatmentNational Cancer Institute2009–2010
- Harvard/Michigan Prostate Cancer Biomarker Clinical CtrNational Cancer Institute2005–2010
- University Of Michigan O'Brien Center For Urology ResearchNational Institute Of Diabetes And Digestive And Kidney Diseases2007
- Survivor Qol/Spouse Satisfaction After Prostate TherapyNational Cancer Institute2004–2007
- Modulating Tolerance For Prostate Cancer Antigen VaccineNational Cancer Institute2003
- Survivor Qol/Spouse Satisfaction After Prostate TherapyNational Cancer Institute2002–2003
- Modulating Tolerance For Prostate Cancer Antigen VaccineNational Cancer Institute2000–2003
- Recombinant Vaccinia/Psa Vaccine In Patients With Recurrence Of Prostate CancerNational Center For Research Resources1998–2002
- Vaccinia PSA For Androgen-Modulated Post-Surgical Recurrence Of Prostate CancerNational Cancer Institute1998–2002
- Targeting PCD In Bladder CancerNational Cancer Institute1998–2002
- Prostate Cancer Gene Therapy With Recombinant VaccinesNational Cancer Institute1996–1999
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: